What Is Tirzepatide? The Dual GIP and GLP-1 Receptor Agonist, Explained

Published October 2026 · Patriot Labs Research Team · ~17 min read

The short answer

Tirzepatide is a 39-amino-acid synthetic peptide that activates two receptors: the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). Those are the receptors for the body’s two incretin hormones, the gut-derived signals that amplify insulin release after a meal. Its backbone is modeled on GIP, it carries a C20 fatty-diacid side chain that binds serum albumin and stretches its half-life to about five days, and it was the first dual GIP/GLP-1 agonist to reach regulatory approval.^[2][10][11]

Two features make it more than “GLP-1 plus GIP.” First, it is imbalanced: it binds the GIP receptor about as tightly as native GIP does, but binds the GLP-1 receptor roughly five times more weakly than native GLP-1.^[2][3] Second, it is biased: at the GLP-1 receptor it favors the cAMP signaling pathway over β-arrestin recruitment and drives less receptor internalization than GLP-1 itself.^[3] Much of the research interest in Tirzepatide is about whether, and how, those two properties matter.

The rest of this guide takes those ideas in order: the hormone system, the molecule, the pharmacology, the research record, and how it compares with its single- and triple-agonist neighbors. For the broader family, see our Retatrutide vs Tirzepatide vs Semaglutide comparison.

The incretin system: GIP and GLP-1

The term incretin describes a simple observation: glucose taken by mouth triggers far more insulin release than the same glucose given intravenously. The difference is made by hormones released from the gut in response to nutrients. Two hormones account for most of that effect: GIP, secreted by K cells in the upper small intestine, and GLP-1, secreted by L cells further down the gut.^[1]

In a 2019 review of the incretin system in healthy humans, Holst described the two hormones as additive in their effect on glucose tolerance, with GIP the more important of the two for insulin secretion and GLP-1 acting substantially through suppression of glucagon.^[1] Both receptors are class B G-protein-coupled receptors that signal mainly through Gαs and cAMP, but they are expressed in different tissue patterns. GLP-1 receptors are prominent in the pancreas, the gut and appetite-regulating regions of the brain; GIP receptors are found on pancreatic islet cells, in adipose tissue and in the central nervous system.

Native GIP and GLP-1 are both cleared within minutes. The enzyme dipeptidyl peptidase-4 (DPP-4) cuts two residues off the N-terminus of each, inactivating them, and the kidneys remove what is left. That short life is the central engineering problem for any research or therapeutic incretin analog: the molecule has to survive DPP-4 and stay in circulation long enough to study.

Why a dual agonist

The first generation of incretin-based molecules targeted GLP-1R alone. Semaglutide, the best-known example, is a GLP-1 analog with a C18 fatty-diacid side chain that gives it a long-acting profile.^[5] GIP was largely set aside for years, partly because its insulin-releasing effect appeared blunted in type 2 diabetes and partly because some rodent genetics suggested that blocking GIP signaling, rather than activating it, protected against diet-induced weight gain.

The dual-agonist idea rests on a different reading: that the two receptors act on overlapping but distinct tissues, so engaging both in a single molecule might reach more of the metabolic network than either alone. Tirzepatide was Eli Lilly’s answer to that question. It was disclosed in 2018 under the code name LY3298176, in a Molecular Metabolism paper that took it from chemistry through mouse pharmacology to early human studies.^[2]

In the progression of incretin research, Tirzepatide is the middle step: a single agonist (semaglutide, GLP-1R only), a dual agonist (Tirzepatide, GIPR plus GLP-1R) and a triple agonist (Retatrutide, which adds the glucagon receptor). Our Retatrutide explainer covers that third receptor.

How the molecule is built

Tirzepatide is a linear 39-amino-acid peptide whose sequence is derived from the N-terminal portion of native GIP, with residues adjusted so that it also engages the GLP-1 receptor.^[2] Three structural modifications do most of the work:

• Two Aib residues. The alanines at positions 2 and 13 are replaced with α-aminoisobutyric acid (Aib), a non-coded amino acid with two methyl groups on its alpha carbon. Aib at position 2 makes the N-terminus a poor substrate for DPP-4, the enzyme that inactivates native GIP and GLP-1, without a large change in receptor binding.^[2][4]
• A lipidated lysine. The lysine at position 20 carries a C20 fatty diacid (eicosanedioic acid), attached through a hydrophilic linker. That side chain is what lets the molecule bind serum albumin.^[2][4]
• An amidated C-terminus. The final serine is a C-terminal amide rather than a free acid, a common modification that removes a negative charge and adds resistance to carboxypeptidases. Our guide to amidation covers why.

At roughly 4.8 kDa, Tirzepatide is large for a synthetic peptide and carries a non-peptide lipid moiety, which makes its manufacture and analysis more demanding than for a short, unmodified sequence. For context on how molecules like this are assembled, see What Is Solid-Phase Peptide Synthesis; for the purity questions they raise, see Peptide Impurities Explained.

Engineered for duration: the fatty-acid side chain

A peptide of Tirzepatide’s size would normally be filtered by the kidneys quickly. The C20 diacid side chain changes that. Fatty diacids bind reversibly to serum albumin, the most abundant protein in blood, and an albumin-bound peptide is too large to be filtered and is shielded from many proteases. The bound fraction acts as a circulating reservoir that slowly releases free peptide. This strategy, called lipidation, is one of the main tools of half-life extension.

In the human pharmacology reported with the 2018 disclosure, Tirzepatide’s mean half-life was approximately 5 days (116.7 hours).^[2] Semaglutide uses the same idea with a C18 diacid; the 2018 commentary accompanying the Tirzepatide paper described it as carrying “lipidation as observed in semaglutide but with a slightly longer fatty acid.”^[2][5]

The albumin binding has a side effect worth understanding when reading in-vitro data: it changes how potent the molecule appears. Willard and colleagues measured a dissociation constant for Tirzepatide binding to albumin of about 1.86 μM, and found that adding albumin to receptor assays shifted its apparent potency 26-fold at GIPR and 81-fold at GLP-1R.^[3] Potency figures measured with and without albumin are therefore not directly comparable, and the albumin effect is larger at one receptor than the other.

An imbalanced agonist

“Dual agonist” can suggest equal activity at both receptors. Tirzepatide does not have that. In the binding and signaling measurements reported by Coskun and colleagues:^[2]

The 2018 commentary summarized it as a molecule “imbalanced in favor of GIP activity ∼4–5x based upon relative affinity and activity measurements to native hormones.”^[2] Willard’s later characterization agreed on the direction. Tirzepatide matched native GIP at GIPR and showed about five-fold weaker binding at GLP-1R than native GLP-1, with a larger gap, around 18- to 20-fold, in cAMP potency in their assays.^[3]

The imbalance is deliberate, not a flaw. It means the GIP side of the molecule is never the weaker partner relative to the GLP-1 side. In Willard’s modeling of predicted receptor occupancy, GIP receptor occupancy was consistently higher than GLP-1 receptor occupancy.^[3] Whether that weighting explains any of the molecule’s research profile is still an open question.

A biased agonist at the GLP-1 receptor

G-protein-coupled receptors do not have a single “on” state. Once activated, a receptor can signal through G proteins, generating second messengers such as cAMP, and it can recruit β-arrestins, which dampen G-protein signaling and pull the receptor into the cell (internalization). A ligand that activates these pathways in different proportions than the native hormone is called a biased agonist.

The 2020 JCI Insight paper by Willard and colleagues, titled “Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist,” reported that at the GLP-1 receptor Tirzepatide:^[3]

• shows bias that favors cAMP generation over β-arrestin recruitment;
• behaves as a partial agonist for G-protein activation, about 51% efficacious in a Gαs GTPγS assay, with very low efficacy (under 10%) for β-arrestin-2 recruitment;
• has a weaker ability to drive GLP-1 receptor internalization than GLP-1 itself.

At the GIP receptor, by contrast, Tirzepatide and native GIP drove receptor internalization comparably.^[3] The bias is specific to the GLP-1 side.

Why this matters as a research question: β-arrestin recruitment and internalization are part of how cells stop responding to a sustained signal. A GLP-1R agonist that recruits less β-arrestin and internalizes the receptor less might keep more receptor at the cell surface over time. In isolated mouse islets, Willard’s group found that deleting β-arrestin-1 in beta cells increased insulin secretion in response to GLP-1 but not in response to Tirzepatide or GIP, which fits with Tirzepatide engaging the GLP-1 receptor in a way that already sidesteps much of the β-arrestin pathway.^[3] These are cell and islet findings. They describe receptor behavior in those models and do not, on their own, predict outcomes in a whole organism.

What the receptor structures show

In 2022, Sun, Willard and colleagues published cryo-electron microscopy structures of Tirzepatide bound to both the GIP receptor and the GLP-1 receptor in complex with their G proteins, in a PNAS paper titled “Structural determinants of dual incretin receptor agonism by tirzepatide.”^[4] Structures like these show how a single peptide sequence fits two different receptor binding pockets: which residues of the ligand contact which parts of each receptor, and why the fit is tighter at one receptor than the other.

One practical point from the structural record: the C20 fatty diacid is not resolved in the deposited GLP-1R model (PDB 7RGP). It appears to be flexible rather than packed against the receptor, consistent with its role as an albumin anchor rather than a receptor-binding element.^[4] Structural studies of this kind are the basis for the next round of incretin design, including the triple agonists.

What the preclinical work found

The 2018 disclosure paper reported a set of mouse and isolated-islet experiments. All of the following are findings in those models:^[2]

• Diet-induced obese (DIO) mice. Chronic administration produced a dose-dependent decrease in body weight that was greater than that seen with semaglutide in the same study, and the lost mass was mainly fat mass.
• Food intake and energy expenditure. The reduction in food intake was larger and more prolonged during the first 7–10 days, and a slight but significant increase in energy expenditure appeared after about a week in Tirzepatide-treated mice, but not in semaglutide-treated mice.
• Receptor knockouts. Tirzepatide stimulated glucose-dependent insulin secretion in islets from wild-type mice and from mice lacking either the GIP receptor or the GLP-1 receptor. That is the expected signature of a molecule acting through both receptors: knocking out one leaves the other.
• GLP-1R blockade. When the GLP-1 receptor was pharmacologically blocked, semaglutide’s glucose-lowering effect was abolished, while Tirzepatide’s was only marginally affected.

The accompanying commentary noted that in DIO mice the weight change was not fully explained by the reduction in food intake, which the author read as pointing to an additional mechanism beyond appetite.^[2] That observation is one of the threads that led researchers to look harder at what the GIP arm contributes.

The GIP receptor paradox

Tirzepatide sits in the middle of one of the more interesting puzzles in metabolic research. In rodents, activating the GIP receptor (as Tirzepatide does) and blocking it (as GIPR antagonist programs do) have both been associated with reduced body weight, especially when combined with GLP-1R agonism. Two opposite pharmacological approaches producing a similar direction of effect is not what simple receptor pharmacology would predict.

Campbell’s 2021 review in Molecular Metabolism, “Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms,” lays out the competing explanations.^[6] One idea is that prolonged agonist exposure desensitizes the GIP receptor in some tissues, so a long-acting agonist ends up partly resembling an antagonist there. Another is that the receptor plays different roles in different tissues, such as adipose tissue, the brain and islets, so the net effect depends on where it is activated. A third is that the effect seen with dual agonists comes from GIP signaling interacting with GLP-1 signaling, rather than from GIP alone.

The question is not settled. For anyone reading the Tirzepatide literature, it is a reminder that a dual agonist’s effects cannot be assumed to equal the sum of its parts, and that the GIP arm’s role remains an active area of investigation.

Clinical research and regulatory history

Tirzepatide moved through a large clinical program, which is part of why it is so widely used as a reference compound. Three of the published trials show the shape of that program:

Each trial reported that its primary endpoints favored Tirzepatide over its comparator; the full results, including adverse-event data, are in the cited papers.^[7][8][9] SURPASS-2 is notable as a head-to-head trial against a single GLP-1R agonist, which is why it is often cited in discussions of whether adding GIP agonism changes the profile of an incretin molecule.

On the regulatory side, the U.S. Food and Drug Administration approved Tirzepatide as Mounjaro for type 2 diabetes on May 13, 2022, then as Zepbound for chronic weight management on November 8, 2023.^[10][11] In December 2024 Zepbound received an additional approval for moderate-to-severe obstructive sleep apnea in adults with obesity.^[10]

That history should be read for what it is. The approved products are finished, sterile pharmaceutical preparations made and released under drug-manufacturing regulations, for use under prescription. Research-grade Tirzepatide is not that product. It is a laboratory chemical supplied for in-vitro research, and nothing in the clinical record above describes it or applies to it.

Tirzepatide vs semaglutide vs Retatrutide

The three molecules are best understood as steps in receptor coverage rather than as stronger and weaker versions of the same thing:

Because Tirzepatide sits between the other two, it is a natural comparator in experiments asking what each added receptor contributes. It is also often studied alongside Cagrilintide, an amylin analog that works through a separate, non-incretin pathway. See What Is Cagrilintide? and our metabolic research overview for that wider picture.

In the laboratory

Research Tirzepatide is supplied as a lyophilized (freeze-dried) powder. A few properties of the molecule are worth keeping in mind when handling it:

• It is a lipidated peptide. The fatty-acid side chain makes the molecule more amphiphilic than an unmodified peptide of the same length, which can affect how readily it dissolves and how it behaves at surfaces. Our guides on reconstitution and pH and mixing cover the general principles.
• Cold and dark. Like other research peptides, the sealed vial is kept cold and protected from light and moisture, and reconstituted solution is refrigerated and protected from repeated freeze–thaw cycles. See cold-chain storage and how peptides degrade.
• Read the certificate. For a 39-residue lipidated peptide, identity by mass spectrometry and purity by HPLC are the minimum. Understanding Peptide COA Testing explains what each figure on a certificate does and does not tell you, including the difference between purity and net peptide content.

For reference, Patriot Labs is a first-responder-owned, US-based company. Its batches are tested by independent US laboratories for purity by HPLC and identity by mass spectrometry, and certificates of analysis are published on product pages as they are issued.

What this guide does not establish

This guide is an educational account of Tirzepatide’s chemistry, pharmacology and research history. Several limits are worth stating plainly.

• Cell, islet and mouse findings stay in their models. Receptor bias, internalization and knockout-islet results describe behavior in those systems. They do not, by themselves, predict effects in a whole organism, let alone a person.
• The clinical trials concern an approved drug product. They were run with a pharmaceutical-grade product under medical supervision. They are summarized here as regulatory and research history only, and they say nothing about any research-grade material.
• The GIP question is open. How much of Tirzepatide’s research profile comes from GIPR agonism, and through which tissues, is still debated.^[6]
• Potency numbers depend on the assay. In-vitro potency values vary with cell system, readout and especially whether albumin is present, so figures from different papers should not be compared directly.^[3]
• Nothing here concerns use in a person or animal. This guide gives no amounts, schedules or methods of use for any product.

Frequently asked questions

What is Tirzepatide?

Tirzepatide is a 39-amino-acid synthetic peptide that acts as a dual agonist of the GIP and GLP-1 receptors, the receptors for the body’s two incretin hormones. Its sequence is based on native GIP, and it carries a C20 fatty-diacid side chain that binds albumin and gives it a half-life of about five days.

How does Tirzepatide work?

It binds and activates both the GIP receptor and the GLP-1 receptor, which signal mainly through cAMP. It is imbalanced, with GIP-receptor affinity comparable to native GIP but GLP-1-receptor affinity about five-fold weaker than native GLP-1, and at the GLP-1 receptor it is biased toward cAMP signaling over β-arrestin recruitment.

What is the difference between Tirzepatide and semaglutide?

Semaglutide is a single agonist that activates only the GLP-1 receptor. Tirzepatide is a dual agonist that activates both the GIP and GLP-1 receptors. Both use a fatty-diacid side chain for albumin binding: C18 for semaglutide, C20 for Tirzepatide.

What is the difference between Tirzepatide and Retatrutide?

Tirzepatide activates two receptors, GIP and GLP-1. Retatrutide is a triple agonist that also activates the glucagon receptor, which is linked to hepatic and energy-expenditure pathways that dual agonists do not engage.

What does “imbalanced and biased” mean?

“Imbalanced” means the molecule is not equally active at its two receptors; Tirzepatide favors the GIP receptor. “Biased” means that at the GLP-1 receptor it activates the cAMP pathway more than the β-arrestin pathway, and drives less receptor internalization than native GLP-1.

Is Tirzepatide FDA approved?

The active molecule is in FDA-approved prescription products: Mounjaro, approved in 2022 for type 2 diabetes, and Zepbound, approved in 2023 for chronic weight management. Research-grade Tirzepatide is not those products. It is sold strictly for in-vitro research and laboratory use and is not for human or veterinary use.

Why is Tirzepatide a peptide and not a small molecule?

Because it is a chain of amino acids, 39 of them, modeled on the GIP hormone. Its size, its Aib substitutions and its fatty-acid side chain are all peptide-engineering choices, which is why it is made by peptide synthesis and analyzed by HPLC and mass spectrometry.

References

1. Holst, J. J. (2019). The incretin system in healthy humans: The role of GIP and GLP-1. Metabolism, 96, 46–55. doi:10.1016/j.metabol.2019.04.014
2. Coskun, T., Sloop, K. W., Loghin, C., et al. (2018). LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Molecular Metabolism, 18, 3–14. doi:10.1016/j.molmet.2018.09.009. With accompanying commentary: DiMarchi, R. D. (2018). “Let’s Stay Together”; GIP and GLP-1 dual agonism in the treatment of metabolic disease. Molecular Metabolism, 18, 1–2. doi:10.1016/j.molmet.2018.10.004
3. Willard, F. S., Douros, J. D., Gabe, M. B. N., et al. (2020). Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight, 5(17), e140532. doi:10.1172/jci.insight.140532
4. Sun, B., Willard, F. S., Feng, D., et al. (2022). Structural determinants of dual incretin receptor agonism by tirzepatide. Proceedings of the National Academy of Sciences, 119, e2116506119. doi:10.1073/pnas.2116506119. Structure and molecular data via RCSB PDB-101: https://pdb101.rcsb.org/global-health/diabetes-mellitus/drugs/incretins/drug/tirzepatide/tirzepatide
5. Lau, J., Bloch, P., Schäffer, L., et al. (2015). Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. Journal of Medicinal Chemistry, 58, 7370–7380. doi:10.1021/acs.jmedchem.5b00726
6. Campbell, J. E. (2021). Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms. Molecular Metabolism, 46, 101139. doi:10.1016/j.molmet.2020.101139
7. Rosenstock, J., Wysham, C., Frías, J. P., et al. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet, 398(10295), 143–155. doi:10.1016/S0140-6736(21)01324-6
8. Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503–515. doi:10.1056/NEJMoa2107519
9. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216. doi:10.1056/NEJMoa2206038
10. Drugs.com. Zepbound (tirzepatide) FDA Approval History, including the approval of Mounjaro (tirzepatide) for type 2 diabetes on May 13, 2022 and the obstructive sleep apnea indication on December 20, 2024. https://www.drugs.com/history/zepbound.html
11. U.S. Food and Drug Administration (November 8, 2023). FDA Approves New Medication for Chronic Weight Management. https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management

For the wider family, see Retatrutide vs Tirzepatide vs Semaglutide, What Is Retatrutide? and What Is Cagrilintide?. For the chemistry behind the molecule, see What Is Lipidation? and Peptide Half-Life Extension.

All Patriot Labs products are sold strictly for in-vitro research and laboratory use only. Not for human or veterinary consumption. This guide is educational and describes the chemistry, pharmacology and published research history of Tirzepatide in general terms; it is not medical advice, does not describe how to use any product, and makes no claim about outcomes in humans. References to approved drug products are regulatory history only; research-grade material is not an approved drug.